October 5, 2022
Chicago 12, Melborne City, USA
Health

Panel Addresses Ezetimibe, PCSK9 Inhibitors for Reducing CV Events – Consumer Health News

[ad_1]

Thursday, May 5, 2022 (HealthDay News) – In a clinical practice guide published online May 4 BMJ, Low-density lipoprotein (LDL) cholesterol levels> 1.8 mmol / L (> 70 mg / dL) for those who are already taking the highest dose of statins or who are intolerant to statins.

Kiqui Hao, MD, of Sichuan University in Chengdu, China, and colleagues reviewed evidence from 14 trials with 83,660 participants on whether to add another lipid-lowering drug to adults with LDL cholesterol levels> 70 mg / dL. Intolerance to the highest dose of statins or statins.

The recommendations made by the panel were mostly weak, so it was advisable to make a decision to share with patients when applying them. The panel states that for adults with LDL cholesterol> 70 mg / dL, the addition of a lipid-lowering drug is not recommended for those at high doses of statins or intolerant to statins, who are at low cardiovascular risk. When considering the addition of a lipid-lowering drug for those with high doses of statins or intolerance to statins for high or very high cardiovascular risk, ezetimib is recommended to be given preference to the protein conversion subtilisin / kexin 9 (PCSK9) inhibitor.

“Due to the large variability expected in patient quality and preferences, well-known choices are guaranteed to be shared,” the author writes.

Abstract / Full text

[ad_2]

Source link

Leave feedback about this

  • Quality
  • Price
  • Service

PROS

+
Add Field

CONS

+
Add Field
Choose Image
Choose Video
X